Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HUMEGON vs ANDEMBRY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Induction of ovulation in women with oligomenorrhea or anovulation not due to primary ovarian failure,Stimulation of multiple follicle development in ovulatory women participating in assisted reproductive technology (ART) programs,Induction of spermatogenesis in men with hypogonadotropic hypogonadism (in combination with h CG)
Castration-resistant prostate cancer (chemotherapy-naïve or docetaxel-treated),Metastatic castration-resistant prostate cancer
75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
Terminal half-life approximately 23-24 hours (range 20-30 h) for FSH and LH activity; clinical significance: once-daily dosing achieves steady-state in 4-5 half-lives (approx. 5 days).
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
The metabolic pathway of menotropins is not fully characterized; however, it is likely degraded via proteolysis into smaller peptides and amino acids in the liver and kidneys.
Hepatic via CYP3A4; active metabolites include abiraterone sulfate, abiraterone N-oxide, and abiraterone glucuronide.
Primarily renal (90-95% as intact hormone and metabolites); biliary/fecal excretion minor (<5%).
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Approximately 30-40% bound to serum albumin; no specific binding proteins identified.
Approximately 95% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
Approximately 0.3-0.5 L/kg (total body water); indicates distribution primarily into extracellular fluid.
Volume of distribution is 0.6-0.8 L/kg, indicating distribution into total body water and some tissue binding.
IM/SC: Approximately 80-90% absolute bioavailability (due to first-pass hepatic metabolism with oral route being ineffective).
Oral bioavailability is 85-90%; intravenous administration yields 100% bioavailability.
No specific dose adjustment guidelines; use caution in severe renal impairment.
No dose adjustment required for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min). Not studied in severe renal impairment (Cr Cl <30 m L/min) or end-stage renal disease; avoid use.
No specific dose adjustment guidelines; use caution in severe hepatic impairment.
Mild hepatic impairment (Child-Pugh A): no dose adjustment. Moderate hepatic impairment (Child-Pugh B): reduce dose to 320 mg orally twice daily. Severe hepatic impairment (Child-Pugh C): not recommended.
Not indicated for use in pediatric patients.
Safety and efficacy not established in pediatric patients (<18 years); no recommended dose.
Not indicated for use in geriatric patients.
No specific dose adjustment required based on age. Monitor renal function and for increased risk of adverse events (e.g., diarrhea, hyperglycemia) in elderly patients.
HUMEGON should only be used by physicians who are experienced in infertility treatment and familiar with the potential risks. The drug has been associated with serious pulmonary and vascular events, including thromboembolism, ovarian hyperstimulation syndrome (OHSS), and multiple pregnancies. Female patients should be advised of the risk of OHSS and multiple gestations.
None.
Risk of Ovarian Hyperstimulation Syndrome (OHSS): may progress to severe form with ascites, pleural effusion, oliguria, and thromboembolic events.,Thromboembolic events: increased risk especially in patients with predisposing factors.,Ovarian torsion: reported in post-treatment period.,Multiple pregnancies: high incidence, especially with higher doses.,Ovarian enlargement: may be asymptomatic or cause abdominal pain.,Ectopic pregnancy: increased risk in patients with tubal disease.,Congenital malformations: incidence may be slightly higher than spontaneous pregnancies.,Monitoring: requires ultrasound and estradiol levels to minimize risks.
Hepatotoxicity, mineralocorticoid excess, cardiovascular events, adrenal insufficiency, and bone marrow suppression.
High levels of FSH indicating primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Pituitary tumor,Abnormal uterine bleeding of undetermined origin,Ovarian cyst or enlargement not due to polycystic ovary syndrome (PCOS),Sex hormone-dependent tumors (e.g., breast, uterus, ovary, prostate),Pregnancy,Hypersensitivity to menotropins or any component
Hypersensitivity to abiraterone acetate or any component, severe hepatic impairment (Child-Pugh C), and women who are or may become pregnant.
No specific food interactions documented. Maintain a balanced diet; no restrictions necessary.
ANDEMBRY can be taken with or without food. However, grapefruit and grapefruit juice may increase trofinetide levels; avoid concurrent consumption. No other significant food interactions reported.
HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic effects have been reported from inadvertent exposure during early pregnancy, but fetal risks include increased incidence of multiple births and associated prematurity, low birth weight, and perinatal morbidity. Avoid use during pregnancy.
Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth restriction. Contraindicated in pregnancy.
It is not known whether menotropins are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when administered to a nursing woman. No M/P ratio is available.
Excreted in human milk; M/P ratio unknown. Potential for serious adverse effects in nursing infant. Contraindicated during breastfeeding.
HUMEGON is contraindicated during pregnancy. No dosing adjustments in pregnancy are applicable as it is not used during pregnancy.
Do not use in pregnancy. No dose recommendations available; contraindicated.
Humegon (menotropins) contains FSH and LH activity. Monitor estradiol levels and follicular growth via ultrasound to adjust dosing and minimize OHSS risk. Administer IM or SC; reconstitute with provided diluent and use immediately. Avoid in primary ovarian failure. Combine with h CG for final oocyte maturation.
ANDEMBRY (trofinetide) is indicated for the treatment of Rett syndrome. Administer orally twice daily with or without food. Monitor for diarrhea and vomiting, which are common adverse effects; consider dose reduction or temporary discontinuation if severe. Assess liver enzymes and bilirubin before and during treatment due to potential hepatotoxicity. Avoid use in patients with severe hepatic impairment. Do not crush or chew capsules; for patients unable to swallow, sprinkle contents onto soft food and administer immediately.
Inject exactly as prescribed; do not miss doses.,Report abdominal pain, bloating, nausea, or rapid weight gain immediately (OHSS signs).,Multiple pregnancy is possible; discuss risks.,Store unopened vials in refrigerator; use reconstituted solution promptly.,Avoid alcohol and smoking during treatment.,Inform doctor of all medications, including herbal supplements.
Take ANDEMBRY exactly as prescribed, twice daily with or without food.,If you miss a dose, skip it and take the next dose at the regular time; do not double the dose.,Common side effects include diarrhea and vomiting; inform your doctor if these become severe or persistent.,Avoid alcohol while taking this medication as it may increase the risk of liver injury.,Report any signs of liver problems such as yellowing of skin or eyes, dark urine, or abdominal pain.,Do not crush or chew the capsules; if you have trouble swallowing, open the capsule and mix the contents with a small amount of soft food (e.g., applesauce) and take immediately.,Keep this medication out of reach of children and store at room temperature away from moisture.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HUMEGON vs ANDEMBRY, answered by our medical review team.
HUMEGON is a Gonadotropin that works by HUMEGON (menotropins) is a purified preparation of gonadotropins (follicle-stimulating hormone, FSH, and luteinizing hormone, LH) extracted from the urine of postmenopausal women. It acts by stimulating ovarian follicular growth and maturation in women and spermatogenesis in men via binding to FSH and LH receptors on target cells.. ANDEMBRY is a Gonadotropin that works by Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HUMEGON and ANDEMBRY depend on the specific clinical indication. These are both Gonadotropin agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HUMEGON is: 75 to 150 IU subcutaneously or intramuscularly once daily for 7 to 12 days, adjusted based on follicular response.. The standard adult dose of ANDEMBRY is: ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between HUMEGON and ANDEMBRY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. HUMEGON is classified as Category C. HUMEGON (menotropins) is not indicated for use during pregnancy. Human menopausal gonadotropin is used for ovulation induction and may result in multiple gestations. No teratogenic. ANDEMBRY is classified as Category C. Category X. First trimester: Major congenital malformations (neural tube defects, craniofacial abnormalities). Second/third trimester: Spontaneous abortion, fetal death, growth res. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.